Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer.
Abdul Moiz KhanLubina ArjyalLelas ShamailehMichael SimonPublished in: BMJ case reports (2022)
A woman in her 50s with HER2 (human epidermal growth factor receptor 2) positive, estrogen/progesterone receptor negative, metastatic invasive ductal carcinoma of the breast, presented with acral cyanosis and severe throbbing pain after recent administration of gemcitabine. She was treated with aspirin, heparin, amlodipine, topical nitroglycerin and analgesics. Gemcitabine was discontinued permanently. She had a gradual recovery except for a small necrotic area over the right 4th digit. However, surgical intervention was avoided.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- locally advanced
- tyrosine kinase
- endothelial cells
- advanced non small cell lung cancer
- case report
- high glucose
- squamous cell carcinoma
- randomized controlled trial
- estrogen receptor
- chronic pain
- low dose
- drug induced
- neuropathic pain
- early onset
- pain management
- induced pluripotent stem cells
- type diabetes
- blood pressure
- cardiovascular disease
- postoperative pain
- binding protein